DiaMedica Announces Resignation of Mark Robbins, as Executive Vice President
January 20, 2015 08:07 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Jan. 20, 2015) - DiaMedica Inc. (TSX VENTURE:DMA) announced today that Mark Robbins has resigned his position with the Company to pursue other...
DiaMedica Appoints David Gurvey as Vice President of Finance
January 15, 2015 08:02 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Jan. 15, 2015) - DiaMedica Inc. (TSX VENTURE:DMA) today announced the appointment of Mr. David Gurvey as the Company's Vice President of Finance....
DiaMedica Announces Restructuring
December 09, 2014 18:30 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 9, 2014) - DiaMedica Inc. (TSX VENTURE:DMA) today announced a company-wide restructuring aimed at preserving cash, reducing operating costs and...
DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes
November 17, 2014 08:00 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Nov. 17, 2014) - DiaMedica Inc. (TSX VENTURE:DMA) today announced top-line results of its Phase IIa proof of concept clinical trial of DM199 in...
DiaMedica Cancels Proposed Financing
November 05, 2014 20:28 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Nov. 5, 2014) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
DiaMedica Inc....
DiaMedica Inc. Announces Public Offering
October 22, 2014 15:13 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Oct. 22, 2014) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
DiaMedica Inc....
DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
August 07, 2014 08:00 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Aug. 7, 2014) - DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class...
DiaMedica to Present at InvestMNt Conference on August 6, 2014
July 30, 2014 08:00 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - July 30, 2014) - DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel,...
DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
July 25, 2014 16:30 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - July 25, 2014) - DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel,...
DiaMedica Promotes Mark Robbins to Executive Vice President
July 10, 2014 08:30 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - July 10, 2014) - DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its...